Cross-Sector entity
Of the tracked stories, 2 of 2 also mention SURO Capital, the most common co-covered peer. The clearest coverage concentration is markets: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention SURO Capital, the most common co-covered peer. The clearest coverage concentration is markets: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each. SAB Biotherapeutics appears in 2 tracked Cross-Sector stories from March 17, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SAB Biotherapeutics. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen Downgrade
SABS and SSSS both receive Sell ratings from Wall Street Zen.
SAB-142 Clinical Progress
SAB Biotherapeutics continues enrollment for its Phase 1/2 trial in Type 1 Diabetes.
Strategic Pivot
Company shifts focus from infectious diseases to immunology and chronic conditions.
Wall Street Zen has issued 'Sell' ratings for both SAB Biotherapeutics and SURO Capital, signaling a shift in sentiment for high-risk biotech and venture-backed assets. These downgrades reflect growing analyst caution regarding clinical-stage development timelines and private equity valuation gaps in the 2026 market environment.
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Source: tickerreport.com · tickerreport.com
